H.I.G. Capital News
-
JATENZO is a first-in-class proprietary softgel oral formulation of testosterone undecanoate for testosterone replacement therapy in certain adult men, and the first oral testosterone medicine approved in more than 60 years. 87 percent of hypogonadal men treated with JATENZO in the pivotal Phase 3 study…
-
March 26, 2019 - Apollo Endosurgery Appoints John Barr to Board of Directors
AUSTIN, TX - March 26, 2019 - The Board of Directors of Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced that John Barr has been appointed to Apollo’s Board of Directors…
-
March 26, 2019 - On Target Laboratories Appoints Executive Vice President of Regulatory and Quality
WEST LAFAYETTE, IN - March 26, 2019 - On Target Laboratories, Inc., a privately held biotechnology company that is developing tumor-targeted fluorescent dyes to improve cancer surgery, announced today the appointment of Donna Haire as Executive Vice President of Regulatory and Quality.…
-
MARLBOROUGH, MA – March 25, 2019 - CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System. The HeartLight X3 System is a third…
-
MARLBOROUGH, MA – March 5, 2019 - CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the first enrollments in a clinical study evaluating use of the HeartLight X3 System in an early persistent AFib…
-
Arvelle Therapeutics to receive rights to develop and commercialize cenobamate, an investigational antiepileptic drug developed by SK Biopharmaceuticals, in Europe SK Biopharmaceuticals to receive upfront payment of $100 million and will be eligible for milestone payments of up to $430 million Arvelle…
-
WEST LAFAYETTE, IN – February 12, 2019 - On Target Laboratories, Inc., a privately held biotechnology company that is developing tumor-targeted fluorescent dyes to improve cancer surgery, announced today that the protocol for the company's Phase 3 clinical trial, OTL38 for Intra-operative…
-
February 7, 2019 - H.I.G. Capital Completes Acquisition of Taconic Biosciences
BOSTON – February 7, 2019 – H.I.G. Capital ("H.I.G."), a leading global private equity investment firm with $30 billion of equity capital under management, is pleased to announce that one of its affiliates has partnered with the management team of Taconic Biosciences, Inc., (“Taconic”…
-
February 4, 2019 - Neurana Pharmaceuticals Announces First Patient Enrolled in the STAR Study
SAN DIEGO, CA - February 4th, 2019 - Neurana Pharmaceuticals, a specialty pharmaceutical company focused on the treatment of neuromuscular conditions, today announced that it has enrolled its first patient in the “STAR Study,” a Phase 2 dose ranging study of tolperisone in acute…
-
January 15, 2019 - On Target Laboratories Appoints Vice President of Marketing and Commercialization
WEST LAFAYETTE, IN – January 15, 2019 - On Target Laboratories, Inc., a privately held biotechnology company that is developing tumor-targeted fluorescent dyes to improve cancer surgery, announced today the appointment of Benjamin Lundgren as Vice President of Marketing and Commercialization.…
-
January 14, 2019 - Intact Vascular Announces Presentations at LINC 2019 Annual Meeting
WAYNE, PA - January 14, 2019 - Intact Vascular, Inc., a private medical device company committed to developing solutions for minimally invasive peripheral vascular procedures, today announced the schedule of key presentations to be featured at the annual Leipzig Interventional Course…
-
WAYNE, PA - January 7, 2019 - Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the first commercial use of its Tack Endovascular System® in multiple hospitals within Germany. A novel therapy for dissection…
-
January 2, 2019 - Intact Vascular Announces Enrollment Completion of TOBA II BTK Clinical
WAYNE, PA - January 2, 2019 - Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced its Tack Optimized
-
December 18, 2018 - Apollo Endosurgery, Inc. Announces the Sale of Its Surgical Product Line
AUSTIN, TX - December 18, 2018 - Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced the sale of its Surgical product line, which consists of the Lap-Band® adjustable…
-
November 29, 2018 - CardioFocus Completes Enrollment In HeartLight® X3 Trial
MARLBOROUGH, MA – November 29, 2018 - CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced completed enrollment in a trial to evaluate its next-generation HeartLight® X3 Endoscopic Ablation System. A…
-
AUSTIN, TX - November 27, 2018 - Apollo Endosurgery, Inc. (“Apollo”) (Nasdaq:APEN), a global leader in less invasive medical devices for bariatric and gastrointestinal procedures, announced today the first commercial shipments of the OverStitch™ Sx Endoscopic Suturing System.…
-
CARLSBAD, CA. - November 20, 2018 - Vertiflex® Inc., a leading innovator of advanced, minimally invasive interventions for spinal stenosis, announced additional results from a randomized, controlled trial of its Superion® Indirect Decompression System in patients with lumbar spinal…
-
November 6, 2018 - Intact Vascular Announces Positive One-Year Data from the TOBA II Clinical Trial
WAYNE, PA - November 6, 2018 – Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced at the 15th annual VIVA conference in Las Vegas that its Tack Optimized Balloon Angioplasty II (TOBA II) clinical trial successfully…
-
November 5, 2018 - Intact Vascular Hires Industry Veteran Steve MacKinnon as Vice President of Sales
WAYNE, PA - November 5, 2018 – Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that Steve MacKinnon has joined its senior management team as Vice President of Sales, effective immediately. Reporting to the…
-
WEST LAFAYETTE, IN - October 15, 2018 - On Target Laboratories, Inc., a privately held biotechnology company that is developing tumor-targeted fluorescent dyes to improve cancer surgery, announced today the publication of a study evaluating the effectiveness of On Target Laboratories'…
-
MIAMI – October 11, 2018 - H.I.G. BioHealth Partners (“H.I.G.”), the dedicated healthcare investment affiliate of H.I.G. Capital, a leading global private equity investment firm with over $27 billion of equity capital under management,* recently announced the sale of HyperBranch…
-
WAYNE, PA – August 6 , 2018 - Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced key presentations that will be featured during a CME symposium at the Amputation Prevention (AMP) Conference in Chicago on August…
-
July 11, 2018 - CardioFocus® Announces Full Commercial Launch of HeartLight® System in Japan
MARLBOROUGH, MA – July 11, 2018 - CardioFocus, Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for atrial fibrillation (AF), today announced the commercial launch of its HeartLight Endoscopic Ablation System in Japan. The commercial launch…
-
WAYNE, PA – July 11 , 2018 - Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today welcomed the publication of the iDissection Classification trial results in the current issue of Journal of Invasive Cardiology. Post-percutaneous…
-
DURHAM, NC - June 11, 2018 - HyperBranch Medical Technology, Inc. announced today that on June 8, 2018, after a two-week trial in federal district court in Wilmington, Delaware, an 8-member jury found in favor of HyperBranch on all remaining claims and legal defenses at issue in a patent…